logo
Share SHARE
FONT-SIZE Plus   Neg

Amended: AstraZeneca Granted Marketing Authorisation In Europe For ZINFORO

Amended: replaces "ZINFOROTM" with "ZINFORO" in the headline and entire article.

AstraZeneca (AZN) announced the European Commission has granted Marketing Authorisation to ZINFORO, or ceftaroline fosamil, a new intravenous cephalosporin antibiotic, for the treatment of adult patients with complicated Skin and Soft Tissue Infections or Community Acquired Pneumonia. AstraZeneca said the authorisation makes ZINFORO the only approved cephalosporin monotherapy in Europe with demonstrated clinical efficacy against methicillin-resistant Staphylococcus aureus.

The Marketing Authorization of ZINFORO is based on data from the Phase III clinical trial programme which included four pivotal registration trials, CANVAS 1 and 2 and FOCUS 1 and 2. AstraZeneca said the studies demonstrated consistent clinical efficacy in the treatment of cSSTI and CAP with the recognised tolerability profile of the cephalosporin class.

In 2009, Forest Laboratories Inc. granted AstraZeneca exclusive worldwide commercial rights and co-exclusive development rights for ceftaroline fosamil, excluding US, Canada and Japan. Forest launched ceftaroline fosamil with similar indications under the trade name Teflaro in the US in March 2011.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Japanese messaging service Line Corp. announced its decision to delay the setting of a price range for its initial public offering by one day, until Tuesday, citing the chaos caused by Brexit in global markets. Line was actually planning to announce the IPO price range on Monday, June 27, and the... Fujifilm launched a new version to its tiny instant printer line up. The new upgraded version, Instax Share SP-2, can be used to print photographs from smartphones in a faster pace. China Resources Pharmaceutical Group Ltd. has filed for an initial public offering in Hong Kong stock exchange, which could turn out to be the biggest IPO of drug company this year in Asia. China Resources Pharmaceutical Group aims to raise $1 billion through the IPO. Another Chinese company, Simcere...
comments powered by Disqus
Follow RTT